ReviewHealth care science2024
The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations.
Review in Health care science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- Neuropsychiatry genetics in Africa.Nature communications · 2026Review
- Nanoparticle based drug delivery systems improve antimalarial efficacy and vaccine performance in African research and clinical settings.Discover nano · 2026Review
- Substandard and Falsified Medicines, Regulatory Capacity and Public Health: A Narrative Review With a Focus on Africa.Public health challenges · 2026Review
- Actionable Pharmacogenomics and Essential Medicines: An Analysis of WHO and African Lists for Safer and Efficacious Drug Use.Clinical pharmacology and therapeutics · 2026Review
- Strengthening Pharmacogenomics Implementation in Africa: Challenges and Opportunities - A Narrative Review.Health science reports · 2026Article
- Translational barriers to phage endolysin deployment for antimicrobial resistance control in Africa.Frontiers in antibiotics · 2026Review
- Nearly one in five essential medicines fail quality standards in Africa: A systematic review and meta-analysis of MNCH medicines and antimalarials.PLOS global public health · 2026Article
- The World Health Organization Coalition of Interested Parties Network: a unified and coordinated approach to regulatory system strengthening.Frontiers in medicine · 2026Article
- Current landscape of innovative drug development and regulatory support in China.Signal transduction and targeted therapy · 2025Review
- Reflecting on Achievements and Renewing Our Vision.Health care science · 2025Article
- Perceptions and practices on substandard and falsified medicines in humans and animals in Wakiso district, Uganda: A qualitative study.PloS one · 2025Article
- The African Medicines Agency and Medicines Regulation: Progress, challenges, and recommendations.Health care science · 2024Review
- Ethiopian Pharmaceutical Sector Stakeholder Perspectives on Regulatory Harmonization in IGAD: A Descriptive Study.Inquiry : a journal of medical care organization, provision and financingArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In response to the situation of the African healthcare system, the African Medicines Agency (AMA) was established by the African Union (AU) to regulate access to medicines and support the local manufacture of medications. This study aimed to describe the factors that enabled the establishment of the African Medicines Agency and its successes, challenges, and perceived benefits. We reviewed data sources that explored the progress and challenges of the African Medicines Agency and Medicines Regulation in Africa. The SPIDER framework was used to organise the research focus and to extract the keywords for the literature search. The study data were obtained from PubMed Central, ScienceDirect, and Google Scholar. Out of 249 studies screened, 19 were selected for this narrative review. Critical successes observed in the agency's establishment include the appointment of a Special Envoy, the selection of its headquarters, and the signing of its treaty by 37 member states. However, it is hindered by poor political commitment, differences in risk-benefits interpretation and organizational structure, weak legal and regulatory frameworks, inadequate financial mechanisms, and inadequate political and policy leadership in some member states. The value of AMA in achieving optimal health outcomes and its other benefits must be considered despite the challenges being encountered. Therefore, all member states should adopt the best procedures in signing and ratifying the treaty and implementing associated commitments to improve efficiency and accountability in African medicine regulation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.